CSIMarket Company Name, Ticker, Customers, else..
 
Sangamo Therapeutics Inc   (SGMO)
Other Ticker:  
 
 
Price: $0.9272 $0.09 10.750%
Day's High: $0.9669 Week Perf: 14.85 %
Day's Low: $ 0.82 30 Day Perf: 9.29 %
Volume (M): 4,832 52 Wk High: $ 1.48
Volume (M$): $ 4,480 52 Wk Avg: $0.63
Open: $0.84 52 Wk Low: $0.29



 Market Capitalization (Millions $) 189
 Shares Outstanding (Millions) 204
 Employees 405
 Revenues (TTM) (Millions $) 12
 Net Income (TTM) (Millions $) -250
 Cash Flow (TTM) (Millions $) -41
 Capital Exp. (TTM) (Millions $) 5

Sangamo Therapeutics Inc
Sangamo Therapeutics Inc is a clinical-stage biotechnology company headquartered in Richmond, California, United States.
The company specializes in developing genetic therapies for diseases caused by genetic defects or deficiencies.
Sangamo Therapeutics Inc aims to cure genetic diseases utilizing gene and cellular therapies.
The company's innovative approach involves editing the genetic code of cells to fix the root cause of genetic disorders.
The company's proprietary technology, called zinc finger nuclease (ZFN), enables precise and targeted cutting and editing of the genome.
Sangamo Therapeutics employs various methods and innovative technologies to ensure the delivery of the edited genetic material to the targeted cells.
Sangamo Therapeutics has a wide range of product candidates under different developmental stages, including gene therapies for hemophilia, lysosomal storage disorders, and sickle cell anemia.
Additionally, the company has a pipeline of CAR-T (Chimeric Antigen Receptor T-cell) candidates to treat different cancer types.
Sangamo Therapeutics has established partnerships with other leading pharmaceutical companies, including Pfizer, Novartis, and Sanofi, to co-develop and commercialize its gene therapy products.
Overall, Sangamo Therapeutics Inc is at the forefront of genetic engineering, and it strives to revolutionize the future of medicine by developing gene therapies to provide long-lasting and durable benefits to patients with genetic diseases.


   Company Address: 501 Canal Blvd. Richmond 94804 CA
   Company Phone Number: 970-6000   Stock Exchange / Ticker: NASDAQ SGMO


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Sangamo Therapeutics Inc

SGMO Faces Major Hurdles in Latest Financial Quarter Ending March 31, 2024

The recent financial results of Sangamo Therapeutics Inc paint a grim picture for the biotechnology company. With a staggering decline in revenue and a widening net loss per share, it is no wonder that the company's shares have taken a hit on the stock market.
The fact that Sangamo Therapeutics Inc's shares have fallen by -13.44% over the past 30 days, bringing the year to date performance to -6.11%, indicates that investors are not confident in the company's future prospects. Additionally, the shares are currently trading on the NASDAQ at -36.8% below its 52-week average, further highlighting the lack of investor confidence in the company.
The financial results for the fiscal period ending March 31, 2024, are particularly concerning. With revenue fading by -99.695% to $0.48 million and a net loss per share widening to $-0.27, it is clear that Sangamo Therapeutics Inc is facing significant challenges. The company's net deficit of $-49.089 million for this period is a stark contrast to the bottom line of $21.133 million reported in the same period the year before.
Sangamo Therapeutics Inc

Sangamo Therapeutics Inc Faces Grim Financial Forecast as Revenue Plummets by 92.5%

Sangamo Therapeutics Inc recently reported their financial results for the period of October to December 2023, and the numbers paint a bleak picture for the company. With a staggering decline in revenue of -92.501%, dropping it to a mere $2.04 million, the company is clearly facing significant challenges. This decline is even more alarming when compared to the same period in the previous year, which saw a fall in revenue by -78.272% from $9.40 million.
Furthermore, the net deficit per share has widened to $-0.31, as opposed to the previous financial reporting period where it was $-0.59 per share. This indicates a worsening financial situation and raises concerns about the company's ability to generate profit.
Sangamo Therapeutics Inc

Sangamo Therapeutics Inc's Revenue Plummeted in Q3 2023, But Bright Spots Await

The stock market can be a rollercoaster ride, with highs and lows that can leave investors dizzy. However, even in the face of adversity, there are always opportunities to be found. One such opportunity lies in the Biotechnology & Pharmaceuticals sector, where we find Sangamo Therapeutics Inc.
Sangamo Therapeutics Inc recently reported a disastrous fiscal period. Their revenue took a significant hit, fading by an alarming -64.482% to $9.40 million. Additionally, their net loss per share extended to $-0.59, a drastic change from the previous year's reporting period. These numbers could easily cause concern and make investors hesitant to jump on board.
Sangamo Therapeutics Inc

Sangamo Therapeutics Inc Faces Steep Revenue Plunge and Net Loss in Q2 2023, Raising Concerns for the Future



Sangamo Therapeutics Inc, a Biotechnology & Pharmaceuticals company, recently released their Q2 2023 financial report, and the results have been nothing short of disastrous. With a significant decline in revenue and a widening net loss per share, Sangamo Therapeutics Inc finds itself in a challenging position. This article will delve into the details of the financial report, analyze its impact on the company, and discuss potential future implications.
Revenue Plunge and Net Loss:
According to the financial report, Sangamo Therapeutics Inc witnessed a staggering decline in revenue during the second quarter of 2023. Revenue plummeted by a significant -76.734% to a meager $6.84 million, compared to $157.96 million in the corresponding period a year ago. This decline signifies a significant setback for the company, especially when juxtaposed against the previous financial period's revenue of $0.12 per share.
Sangamo Therapeutics Inc

Sangamo Therapeutics Inc Soars High with Stunning 459% Revenue Increase in Q1 2023

Sangamo Therapeutics Inc has been making waves in the Biotechnology & Pharmaceuticals industry with its notable revenue elevation of 459.516% year on year to $157.96 million in the first quarter of 2023 earnings season. This remarkable accomplishment has taken the company to new heights with a turnaround in earnings, posting an Income per Share at $0.12. This is a massive improvement from the preceding reporting period, where the EPS turned positive from $-0.29 per share, and Revenue doubled by 480.084% from $27.23 million.
The company's outstanding performance is evident in its earnings of $21.133 million in the first quarter of 2023 earnings season versus a net loss of $-43.977 million in the similar reporting period a year ago. This speaks volumes about the company's unwavering dedication to providing top-notch services to its clients while also maintaining a positive bottom line.






Sangamo Therapeutics Inc's Segments





Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com